var data={"title":"Colistin (colistimethate): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Colistin (colistimethate): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5944?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=colistin-colistimethate-drug-information\" class=\"drug drug_general\">see &quot;Colistin (colistimethate): Drug information&quot;</a> and <a href=\"topic.htm?path=colistin-colistimethate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Colistin (colistimethate): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154558\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Coly-Mycin M</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154559\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Coly-Mycin M</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046591\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Miscellaneous</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12669169\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosage expressed in terms of colistin base activity (CBA). <b>CBA 1 mg</b> is defined to be equivalent to<b> colistimethate sodium (CMS) 30,000 units which is equivalent to ~2.4 mg CMS</b> (EMA 2014; Falagas 2006; Kassamali 2013; Nation 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing, susceptible infection:</b> Colistin base: IM, IV: 2.5 to 5 mg CBA/kg/day divided every 6 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pulmonary infection:</b> Limited data available: Colistin base: Inhalation: 4 mg CBA/kg/<b>dose</b> every 12 hours has been used to treat ventilator-associated pneumonia in neonates [n=8, gestational age: 28 to 41 weeks; median treatment duration: 9 days (range: 4 to 14 days)] (Nakwan 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046583\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=colistin-colistimethate-drug-information\" class=\"drug drug_general\">see &quot;Colistin (colistimethate): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: Doses should be based on ideal body weight in obese patients</b>; dosage primarily expressed in terms of colistin base activity (CBA). <b>CBA 1 mg</b> is defined to be equivalent to<b> colistimethate sodium (CMS) 30,000 units which is equivalent to ~2.4 mg CMS</b> (EMA 2014; Falagas 2006; Kassamali 2013; Nation 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b> Infants, Children, and Adolescents: Colistin base: IM, IV: 2.5 to 5 mg CBA/kg/day divided every 6 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>CNS infection (VP-shunt infection, ventriculitis, meningitis), multidrug resistant:</b> Limited data available; variable doses reported; optimal dose not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children: Very limited data available: Intraventricular/Intrathecal: Colistin base: Reported range: 1 to 4.2 mg CBA/dose once daily in combination with systemic antibiotics (Dalgic 2009; IDSA [Tunkel 2017]; Ng 2006; Ozdemir 2010). Doses should be individualized based on culture/sensitivity, MIC, and tolerability while ensuring that patient size and CSF volume are considered. In one case report, a 4-year old with multidrug resistant <i>Acinetobacter baumannii</i> received an intraventricular dose of 1 mg CBA on Day 1, followed by 2 mg CBA once daily for 2 days, then 4 mg CBA once daily; after 13 days, a dose reduction to 2 mg CBA once daily was necessary due to CSF leukocytosis (Ng 2006). A similar protocol was described in a 2-month old with multidrug resistant <i>Acinetobacter baumannii</i>; the initial dose on Day 1 was 1 mg CBA followed by 2 mg CBA once daily for 2 days, then 4 mg CBA once daily; due to failure to sterilize the CSF, the dose was slowly titrated up to 10 mg CBA/day for a total of 20 days (Dalgic 2009). In a case report of a 3-year old with multidrug resistant <i>Acinetobacter baumannii</i>, intrathecal colistin was administered without titration at a dose of 4.2 mg CBA/day (Ozdemir 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: Very limited data available: Intraventricular/Intrathecal: Colistin base: 4.2 mg CBA/day (equivalent to 10 mg <b>CMS</b>/day) (IDSA [Tunkel 2017]; Yagmur 2006); <b>Note:</b> Dose in clinical reports in adults has ranged from 0.7 to 8.3 mg CBA/day in 1 or 2 divided doses (administered with concomitant systemic antimicrobial therapy) (Benifla 2004; Falagas 2007; Imberti 2012; Katragkou 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cystic fibrosis, pulmonary infection:</b> Limited data available: Children &ge;5 years and Adolescents: Colistin base: IV: Usual reported range: 3 to 5 mg CBA/kg/day divided every 8 hours; maximum dose: 100 mg CBA/dose (Bosso 1991; Reed 2001; Young 2013); doses &gt;5 mg CBA/kg/day (up to 8 mg CBA/kg/day) may be required in some situations; however, higher doses are associated with more severe toxicity (Bosso 1991; Reed 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pulmonary infection:</b> Limited data available: Infants, Children, and Adolescents: Colistin base: Inhalation: Usual dose: 75 to 150 mg CBA in 3 mL of NS (4 mL total volume) via nebulizer twice daily is most frequently reported in clinical practice; reported range: 30 to 150 mg CBA/dose (Le 2010; Tramper-Stranders 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Susceptible infections</b>: Colistin base: IM, IV: 2.5 to 5 mg CBA/kg/day in 2 to 4 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Adults: Colistin base: IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;80 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 50 to 79 mL/minute: 2.5 to 3.8 mg CBA/kg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 30 to 49 mL/minute: 2.5 mg CBA/kg/day in 1 to 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 10 to 29 mL/minute: 1.5 mg CBA/kg every 36 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): 1.5 mg CBA/kg every 24 to 48 hours (Heintz 2009). <b>Note:</b> Dosing dependent on the assumption of 3 times/week, complete IHD sessions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CVVH/CVVHD/CVVHDF: 2.5 mg CBA/kg every 24 to 48 hours (frequency dependent upon site or severity of infection or susceptibility of pathogen)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> A single-case report has demonstrated that the use of 2.5 mg CBA/kg every 48 hours with a dialysate flow rate of 1 L/hour may be inadequate and that dosing every 24 hours was well tolerated. Based on pharmacokinetic analysis, the authors recommend dosing as frequent as every 12 hours in patients receiving CVVHDF (Li 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for toxicity</b>: Infants, Children, and Adolescents: Based on experience with other aminoglycosides, the following should be considered: <b></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CNS toxicity: Dose reduction may reduce neurologic symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nephrotoxicity: Withhold treatment if signs of renal impairment occur during treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154544\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection [strength expressed as base, preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Coly-Mycin M: 150 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 150 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154532\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046594\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: Administer deep into a large muscle mass (eg, gluteal muscle or lateral part of the thigh).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV push: Administer over 3 to 5 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent IV infusion: Administer over 30 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous IV infusion: Initially, one-half of the total daily dose is administered by direct IV injection over 3 to 5 minutes followed 1 to 2 hours later by the remaining one-half of the total daily dose diluted in a compatible IV solution infused over 22 to 23 hours. Infusion should be completed within 24 hours of preparation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhalation: Administer solution via nebulizer promptly following preparation of solution to decrease possibility of high concentrations of colistin from forming which may lead to potentially life-threatening lung toxicity. Consider use of a bronchodilator (eg, albuterol) within 15 minutes prior to administration (Le 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> A case report of fatal lung toxicity implicated in vitro colistin formation from an inhalation solution as a potential etiology, but data regarding the concentration, formulation, and storage of the inhaled colistin administered to the patient were not reported (FDA 2007; McCoy 2007; Wallace 2008). An acceptable limit of in vitro colistin formation to prevent potential toxicity is unknown. Limited stability data are available regarding the storage of colistin solution for inhaled administration (Healan 2012; Wallace 2008). Storing for &gt;24 hours may increase the risk for potential lung toxicity; preparation immediately prior to administration is recommended (FDA 2007; Le 2010; Wallace 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intraventricular/Intrathecal: Administer only preservative-free solutions via intrathecal/intraventricular routes. Administer promptly after preparation. Discard unused portion of vial. When administering via a ventricular drain, experts recommend the drain be clamped for 15 to 60 minutes to allow equilibration of colistin with CSF prior to opening the drain (Tunkel [IDSA 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154555\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials (prior to reconstitution) at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Reconstituted vials may be refrigerated at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) or stored at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F) for up to 7 days. Solutions for infusion should be freshly prepared in D5<sup>1</sup>/<sub>4</sub>NS, D5<sup>1</sup>/<sub>2</sub>NS, D5NS, D5W, LR, or NS; do not use beyond 24 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046593\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli (particularly <i>Pseudomonas aeruginosa</i>) which are resistant to other antibacterials (FDA approved in all ages); has also been used as inhalation therapy to treat multidrug-resistant gram-negative pneumonia and in cystic fibrosis; intrathecal/intraventricular therapy to treat multidrug resistant gram-negative meningitis. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14219656\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Due to the potential for dosing errors, it is recommended that prescriptions for colistimethate be expressed as colistin base activity only.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154577\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, neurotoxicity (higher incidence with high-dose IV use in cystic fibrosis [Bosso 1991; Koch-Weser 1970]), oral paresthesia, paresthesia, peripheral paresthesia, seizures, slurred speech, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Clostridium difficile associated diarrhea, gastric distress</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Decreased urine output, nephrotoxicity (Dalfino 2012; Oliveira 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Acute renal failure (Akajagbor 2013; Deryke 2010), decreased creatinine clearance, increased blood urea nitrogen, increased serum creatinine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Apnea, respiratory distress</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154549\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to colistimethate, colistin, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154536\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bronchoconstriction: Use of inhaled colistimethate (off-label route) may result in bronchoconstriction. Use with caution in patients with hyperactive airways; consider administration of a bronchodilator (eg, albuterol) within 15 minutes prior to administration (Le 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CNS toxicity: Transient, reversible neurological disturbances (eg, dizziness, numbness, paresthesia, generalized pruritus, slurred speech, tingling, vertigo) may occur. Patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Dose reduction may reduce neurologic symptoms; monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal toxicity: Dose-dependent nephrotoxicity has been reported, generally reversible upon discontinuation of treatment. Withhold treatment if signs of renal impairment occur during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Respiratory arrest: Respiratory arrest has been reported with use; impaired renal function may increase the risk for neuromuscular blockade and apnea.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with preexisting renal impairment; dosage adjustments are recommended. Impaired renal function may increase the risk for respiratory arrest.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Inhalation (off-label route):  Once mixed, colistimethate begins conversion to bioactive colistin, a component of which may result in severe pulmonary toxicity (Le 2010). Solutions for inhalation must be mixed immediately prior to administration and used within 24 hours to reduce the incidence of pulmonary toxicity. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: IV: Use only to prevent or treat infections strongly suspected or proven to be caused by susceptible bacteria to minimize development of bacterial drug resistance.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Safety: Potential for dosing errors due to lack of standardization in literature when referring to product and dose; colistimethate (inactive prodrug) and colistin base strengths are not interchangeable; verify prescribed dose is expressed in terms of colistin base activity prior to dispensing. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25855510\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Nephrotoxicity is dose dependent and reversible upon discontinuation and has been observed to occur within the first 4 days of therapy in patients with cystic fibrosis (Bosso 1991). The Cystic Fibrosis Foundation recommends that patients not use colistimethate for inhalation premixed by pharmacies; patients should prepare their colistimethate nebulizer inhalation solutions immediately prior to use. Colistin is comprised of two components: Colistin A (polymyxin E1) and colistin B (polymyxin E2). Polymyxin E1 has been shown to cause localized airway inflammation in animal studies and may result in lung toxicity in humans. Clinicians who continue to prescribe colistimethate for inhalation should be aware of this potentially life-threatening effect and should administer solutions for inhalation promptly following preparation of solution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299084\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154540\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13161&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: May enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: May enhance the nephrotoxic effect of Colistimethate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bacitracin (Systemic): Colistimethate may enhance the nephrotoxic effect of Bacitracin (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capreomycin: May enhance the neuromuscular-blocking effect of Colistimethate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefazedone: May enhance the nephrotoxic effect of Colistimethate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: May enhance the nephrotoxic effect of Colistimethate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Colistimethate may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: Colistimethate may enhance the nephrotoxic effect of Methoxyflurane. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Colistimethate may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Polymyxin B: May enhance the neuromuscular-blocking effect of Colistimethate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vancomycin: May enhance the nephrotoxic effect of Colistimethate.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154542\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5105300\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Colistimethate crosses the placenta in humans.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046590\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential, renal function tests, urine output; number and type of stools/day for diarrhea; for inhalation therapy: Pre- and post-treatment spirometry; signs of bronchospasm </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154535\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Colistimethate (or the sodium salt [colistimethate sodium]) is the inactive prodrug that is hydrolyzed to colistin, which acts as a cationic detergent and damages the bacterial cytoplasmic membrane causing leaking of intracellular substances and cell death</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154548\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Not absorbed from the GI tract, mucous membranes, or intact skin (<b>Note:</b> GI absorption has been observed in infants).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Distributes widely, except for CNS, synovial, pleural, and pericardial fluids</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Healthy volunteer:</i> IV: Colistimethate: V<sub>d</sub>: 8.92 L; Colistin: V<sub>d</sub>: 12.4 L (Couet 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Critically ill:</i> IV: Colistimethate: V<sub>d</sub>: 5.3 to 13.5 L; Colistin: V<sub>d</sub>: 7.2 to 189 L (Couet 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cystic fibrosis:</i> Adolescents and Adults: IV: Colistimethate: V<sub>dss</sub>: 0.09 &plusmn; 0.03 L/kg (Reed 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 50%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Colistimethate sodium (inactive prodrug) is hydrolyzed to colistin (active form). <b>Note:</b> Only ~30% of colistimethate sodium is converted to colistin (Couet 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: IM, IV: Colistimethate: 2 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Critically ill:</i> Infants (including premature infants), Children, Adolescents, and Adults: IV: Colistimethate: 2.3 hours; Colistin: 14.4 hours (Plachouras 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cystic fibrosis:</i> IV: Colistin: ~4 hours (Li 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>ESRD patients receiving CAPD:</i> IV: Colistin: 13.2 hours (Koomanachai 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Healthy volunteers:</i> IV: Colistin: 2 hours (range: 1 to 4 hours) (Couet 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Critically ill:</i> IV: Colistin: ~7 hours (Plachouras 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Primarily urine (as unchanged drug)); most colistin recovered in the urine is from postexcretion hydrolysis of colistimethate sodium (Couet 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323078\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Colistimethate Sodium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (1): $33.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Coly-Mycin M Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (1): $33.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038587\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acostin (IN);</li>\n      <li>Aldreb (JP);</li>\n      <li>Alficetin (AR);</li>\n      <li>Alveoxina (AR);</li>\n      <li>Avagal (UY);</li>\n      <li>Colfinair (ES);</li>\n      <li>Colifin (CH, DE);</li>\n      <li>Colimex (LI, QA, SA);</li>\n      <li>Colimicina (IT);</li>\n      <li>Colimycin (CL);</li>\n      <li>Colimycine (FR, SK);</li>\n      <li>Coliracin (IL);</li>\n      <li>Colis (KR);</li>\n      <li>Colistate (TH);</li>\n      <li>Colistimixin (AU);</li>\n      <li>Colistin (CH, HK, NL, PL);</li>\n      <li>Colistin Link (AU, NZ);</li>\n      <li>Colistineb (BE);</li>\n      <li>Colixin (PT);</li>\n      <li>Colmesdant (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Colobreathe (BE, CZ, EE, ES, GB, HU, IE, LT, NL, PL, SE);</li>\n      <li>Colomycin (CZ, GB, GR, HK, HN, IE, MY, SG, SI);</li>\n      <li>Costim (TW);</li>\n      <li>Damacol (LI);</li>\n      <li>Eskcolis (BD);</li>\n      <li>Kolneb (AT);</li>\n      <li>Kolomitsyn (UA);</li>\n      <li>Kolomycin (SK);</li>\n      <li>Mellistin (TH);</li>\n      <li>Promixin (DE, DK, ES, GB, IE, NO);</li>\n      <li>Tadim (AU, GR, NL, SE);</li>\n      <li>Xylistin (IN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P, Charurat ME, Gilliam BL. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. <i>Clin Infect Dis</i>. 2013;57(9):1300-1303.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/23840000/pubmed\" target=\"_blank\" id=\"23840000\">23840000</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Benifla M, Zucker G, Cohen A, Alkan M. Successful treatment of Acinetobacter meningitis with intrathecal polymyxin E. <i>J Antimicrob Chemother</i>. 2004;54(1):290-292. doi: 10.1093/jac/dkh289.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/15190037/pubmed\" target=\"_blank\" id=\"15190037\">15190037</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Beringer P, &ldquo;The Clinical Use of Colistin in Patients With Cystic Fibrosis,&rdquo; <i>Curr Opin Pulm Med</i>, 2001, 7(6):434-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/11706322 [/pubmed\" target=\"_blank\" id=\"11706322 [\">11706322 [</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bosso JA, Liptak CA, Seilheimer DK, et al, &quot;Toxicity of Colistin in Cystic Fibrosis Patients,&quot; <i>DICP</i>, 1991, 25(11):1168-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/1763528/pubmed\" target=\"_blank\" id=\"1763528\">1763528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coly-Mycin M Parenteral (colistimethate) [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Couet W, Gr&eacute;goire N, Gobin P, et al. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. <i>Clin Pharmacol Ther</i>. 2011;89(6):875-879.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/21544080/pubmed\" target=\"_blank\" id=\"21544080\">21544080</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Couet W, Gr&eacute;goire N, Marchand S, Mimoz O. Colistin pharmacokinetics: the fog is lifting. <i>Clin Microbiol Infect</i>. 2012;18(1):30-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/21988234/pubmed\" target=\"_blank\" id=\"21988234\">21988234</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cunningham S, Prasad A, Collyer L, et al, &ldquo;Bronchoconstriction Following Nebulised Colistin in Cystic Fibrosis,&rdquo; <i>Arch Dis Child</i>, 2001, 84(5):432-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/11316693/pubmed\" target=\"_blank\" id=\"11316693\">11316693</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dalfino L, Puntillo F, Mosca A, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. <i>Clin Infect Dis</i>. 2012;54(12):1720-1726.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/22423120/pubmed\" target=\"_blank\" id=\"22423120\">22423120</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dalgic N, Ceylan Y, Sancar M, et al. Successful treatment of multidrug-resistant Acinetobacter baumannii ventriculitis with intravenous and intraventricular colistin. <i>Ann Trop Paediatr</i>. 2009;29(2):141-147.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/19460268/pubmed\" target=\"_blank\" id=\"19460268\">19460268</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. <i>Antimicrob Agents Chemother</i>. 2010;54(10):4503-4505.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/20660694/pubmed\" target=\"_blank\" id=\"20660694\">20660694</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    European Medicine Agency (EMA). European Medicines Agency completes review of polymyxin-based medicine. Published October 24, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Falagas ME and Kasiakou SK, &quot;Use of International Units When Dosing Colistin Will Help Decrease Confusion Related to Various Formulations of the Drug Around the World,&quot;<i> Antimicrob Agents Chemother</i>, 2006, 50(6):2274-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/16723606/pubmed\" target=\"_blank\" id=\"16723606\">16723606</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Falagas ME, Sideri G, Korbila IP, et al, &quot;Inhaled Colistin for the Treatment of Tracheobronchitis and Pneumonia in Critically Ill Children Without Cystic Fibrosis,&quot; <i>Pediatr Pulmonol</i>, 2010, 45(11):1135-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/20658485/pubmed\" target=\"_blank\" id=\"20658485\">20658485</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Healan AM, Gray W, Fuchs EJ, Griffiss JM, Salata RA, Blumer J. Stability of colistimethate sodium in aqueous solution. <i>Antimicrob Agents Chemother</i>. 2012;56(12):6432-6433<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/23070159 /pubmed\" target=\"_blank\" id=\"23070159 \">23070159 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, and Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22687507\"></a>Imberti R, Cusato M, Accetta G, et al. Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration of colistin methanesulfonate. <i>Antimicrob Agents Chemother</i>. 2012;56(8):4416-4421.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/22687507/pubmed\" target=\"_blank\" id=\"22687507\">22687507</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Iosifidis E, Antachopoulos C, Ioannidou M, et al, &quot;Colistin Administration to Pediatric and Neonatal Patients,&quot; <i>Eur J Pediatr</i>, 2010, 169(7):867-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/20119725/pubmed\" target=\"_blank\" id=\"20119725\">20119725</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jajoo M, Kumar V, Jain M, et al, &quot;Intravenous Colistin Administration in Neonates,&quot; <i>Pediatr Infect Dis J</i>, 2011, 30(3):218-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/21245777/pubmed\" target=\"_blank\" id=\"21245777\">21245777</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Karaiskos I, Galani L, Baziaka F, Giamarellou H. Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug-resistant and extensively drug-resistant <i>Acinetobacter baumannii</i> ventriculitis and meningitis: a literature review. <i>Int J Antimicrob Agents</i>. 2013;41(6):499-508.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/23507414/pubmed\" target=\"_blank\" id=\"23507414\">23507414</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kassamali Z, Rotschafer JC, Jones RN, Prince RA, Danziger LH. Polymyxins: wisdom does not always come with age. <i>Clin Infect Dis</i>. 2013;57(6):877-83. doi: 10.1093/cid/cit367.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/23728146/pubmed\" target=\"_blank\" id=\"23728146\">23728146</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Katragkou A and Roilides E, &quot;Successful Treatment of Multidrug-Resistant <i>Acinetobacter baumannii</i> Central Nervous System Infections With Colistin,&quot; <i>J Clin Microbiol</i>, 2005, 43(9):4916-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/16145177/pubmed\" target=\"_blank\" id=\"16145177\">16145177</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. <i>Ann Intern Med</i>. 1970;72(6):857-868.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/5448745/pubmed\" target=\"_blank\" id=\"5448745\">5448745</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koomanachai P, Landersdorfer CB, Chen G, et al. Pharmacokinetics of colistin methanesulfonate and formed colistin in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis. <i>Antimicrob Agents Chemother</i>. 2014;58(1):440-446.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/24189256/pubmed\" target=\"_blank\" id=\"24189256\">24189256</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Le J, Ashley ED, Neuhauser MM, et al, &quot;Consensus Summary of Aerosolized Antimicrobial Agents: Application of Guideline Criteria. Insights From the Society of Infectious Diseases Pharmacists,&quot; <i>Pharmacotherapy</i>, 2010, 30(6):562-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/20500046/pubmed\" target=\"_blank\" id=\"20500046\">20500046</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li J, Rayner CR, Nation RL, et al, &quot;Pharmacokinetics of Colistin Methanesulfonate and Colistin in a Critically Ill Patient Receiving Continuous Venovenous Hemodiafiltration,&quot; <i>Antimicrob Agents Chemother</i>, 2005, 49(11):4814-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/16251342/pubmed\" target=\"_blank\" id=\"16251342\">16251342</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li J, Coulthard K, Milne R, et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. <i>J Antimicrob Chemother</i>. 2003 ;52(6):987-992.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/14585859/pubmed\" target=\"_blank\" id=\"14585859\">14585859</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lim LM, Ly N, Anderson D, et al, &quot;Resurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynamics, and Dosing,&quot; <i>Pharmacotherapy</i>, 2010, 30(12):1279-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/21114395/pubmed\" target=\"_blank\" id=\"21114395\">21114395</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCoy KS. Compounded colistimethate as possible cause of fatal acute respiratory distress syndrome. <i>N Engl J Med</i>. 2007;357(22):2310-2311.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/18046039/pubmed\" target=\"_blank\" id=\"18046039\">18046039</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nakwan N, Wannaro J, Thongmak T, et al, &quot;Safety in Treatment of Ventilator-Associated Pneumonia Due to Extensive Drug-Resistant <i>Acinetobacter baumannii</i> With Aerosolized Colistin in Neonates: A Preliminary Report,&quot; <i>Pediatr Pulmonol</i>, 2011, 46(1):60-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/20812247/pubmed\" target=\"_blank\" id=\"20812247\">20812247</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28011614\"></a>Nation RL, Garonzik SM, Thamlikitkul V, et al. Dosing guidance for intravenous colistin in critically-ill patients. <i>Clin Infect Dis</i>. 2017;64(5):565-571. doi: 10.1093/cid/ciw839.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/28011614/pubmed\" target=\"_blank\" id=\"28011614\">28011614</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24107410\"></a>Nation RL, Li J, Cars O, et al. Consistent global approach on reporting of colistin doses to promote safe and effective use. <i>Clin Infect Dis.</i> 2014;58(1):139-141.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/24107410/pubmed\" target=\"_blank\" id=\"24107410\">24107410</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ng J, Gosbell IB, Kelly JA, Boyle MJ, Ferguson JK. Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review. <i>J Antimicrob Chemother</i>. 2006;58(5):1078-1081.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/16916866/pubmed\" target=\"_blank\" id=\"16916866\">16916866</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity. <i>Diagn Microbiol Infect Dis</i>. 2009;65(4):431-434.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/19733029/pubmed\" target=\"_blank\" id=\"19733029\">19733029</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ozdemir H, Tapisiz A, Cift&ccedil;i E, et al. Successful treatment of three children with post-neurosurgical multidrug-resistant <i>Acinetobacter baumannii</i> meningitis. <i>Infection</i>. 2010;38(3):241-244.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/20358244/pubmed\" target=\"_blank\" id=\"20358244\">20358244</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. <i>Antimicrob Agents Chemother</i>. 2009;53(8):3430-3436.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/19433570/pubmed\" target=\"_blank\" id=\"19433570\">19433570</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reed MD, Stern RC, O'Riordan MA, et al, &quot;The Pharmacokinetics of Colistin in Patients With Cystic Fibrosis,&quot; <i>J Clin Pharmacol</i>, 2001, 41(6):645-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/11402633 /pubmed\" target=\"_blank\" id=\"11402633 \">11402633 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sabuda DM, Laupland K, Pitout J, et al, &quot;Utilization of Colistin for Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i>,&quot; <i>Can J Infect Dis Med Microbiol</i>, 2008, 19(6):413-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/19436571/pubmed\" target=\"_blank\" id=\"19436571\">19436571</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tramper-Stranders GA, Wolfs TF, van Haren Noman S, et al, &quot;Controlled Trial of Cycled Antibiotic Prophylaxis to Prevent Initial <i>Pseudomonas aeruginosa</i> Infection in Children With Cystic Fibrosis,&quot; <i>Thorax</i>, 2010, 65(10):915-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/20729233/pubmed\" target=\"_blank\" id=\"20729233\">20729233</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &quot;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&quot; <i>Clin Infect Dis</i>, 2005, 41:1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis. <i>Clin Infect Dis</i>. 2017 Feb 14. [Epub ahead of print]<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/28203777/pubmed\" target=\"_blank\" id=\"28203777\">28203777</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Food and Drug Administration (FDA). Information for Healthcare Professionals: Colistimethate (marketed as Coly-Mycin M and generic products). FDA Alert June 28, 2007. <a href=\"http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124896.htm\" target=\"_blank\">http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124896.htm</a>. Updated August 14, 2013. Accessed January 31, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wallace SJ, Li J, Rayner CR, Coulthard K, Nation RL. Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients. <i>Antimicrob Agents Chemother</i>. 2008;52(9):3047-3051.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/18606838 /pubmed\" target=\"_blank\" id=\"18606838 \">18606838 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yagmur R, Esen F. Intrathecal colistin for treatment of <i>Pseudomonas aeruginosa</i> ventriculitis: report of a case with successful outcome. <i>Crit Care</i>. 2006;10(6):428.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/17214907/pubmed\" target=\"_blank\" id=\"17214907\">17214907</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Young DC, Zobell JT, Waters CD, et al, &quot;Optimization of Anti-pseudomonal Antibiotics for Cystic Fibrosis Pulmonary Exacerbations: IV. Colistimethate Sodium,&quot;<i> Pediatr Pulmonol</i>, 2013, 48(1):1-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-pediatric-drug-information/abstract-text/22949160/pubmed\" target=\"_blank\" id=\"22949160\">22949160</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13161 Version 128.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F154558\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F154559\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1046591\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F12669169\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1046583\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F154544\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F154532\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1046594\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F154555\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1046593\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F14219656\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F154577\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F154549\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F154536\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25855510\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299084\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F154540\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F154542\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5105300\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1046590\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F154535\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F154548\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323078\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038587\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13161|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=colistin-colistimethate-drug-information\" class=\"drug drug_general\">Colistin (colistimethate): Drug information</a></li><li><a href=\"topic.htm?path=colistin-colistimethate-patient-drug-information\" class=\"drug drug_patient\">Colistin (colistimethate): Patient drug information</a></li></ul></div></div>","javascript":null}